

PAHO REGULATORY RESPONSE COVID19 PANDEMIC FIFARMA ANNUAL REGIONAL VIRTUAL MEETING

Charles Preston, MD, MPH

Advisor, Regulatory System Strengthening for Medicines and Other Health Technologies
PAHO/WHO




PAHO

Overview of Presentation

- PAHO Medicines and Health Technologies Unit
- COVID work
- COVID regulatory work
 - Where are there strategic partnerships?
- Any questions

Organizational Context



- PAHO is regional arm of WHO for the Americas
- PAHO has local offices in most of the 35 countries in the Americas
- PAHO Medicines and Health Technologies (MT) Unit is situated in the Department of Health Systems and Services in Washington, DC
- Other departments include: communicable diseases and environmental determinants of health; non-communicable diseases and mental health; family, health promotion and life course; and evidence and intelligence for action in health

Organizational Context

- The MT unit is comprised of advisors and technical experts including:
 - regulatory strengthening,
 - rational use, essential meds, antimicrobial resistance, pharmacovigilance, evidence
 - medical devices and health technology assessment,
 - blood and blood products,
 - supply chain,
 - pharmaceutical policy and access to medicines,
 - radiation and radiological devices,
 - PAHO Strategic and Revolving Fund quality assurance,

PAHO Emergency Response

- Incident Management Structure, manager
- Within Emergency Operations Center
- Persons divided into different thematic areas-
 - Medicines and health technology work is within the cluster that includes health systems, workers, medicines, evidence, etc.

Types of Requests Driving PAHO's Response

- Country requests for information
- Country requests for technical cooperation
- Country requests for norms, standards, guidance
- Country requests for help with procurement



Specific Topic Areas to Date

- Quality standards and procurement of personal protective equipment
- Advice on and quality standards of test kits
- Advice on and quality standards of ventilators
- Advice on medicines, convalescent plasma
- Joining SOLIDARITY clinical trial
- Local production

[Health Topics](#) ▾[Countries](#) ▾[Newsroom](#) ▾[Emergencies](#) ▾[About Us](#) ▾[Home](#) / [Emergencies](#) / [Diseases](#) / Coronavirus disease 2019

Coronavirus disease (COVID-19) Pandemic

[Public advice](#)[Country and
technical
guidance](#)[Donate](#)[Your questions
answered](#)

UPCOMING : Press Conference, Wednesday 13.05.2020 5 < >

[Travel advice](#)[Situation
reports](#)[Media
resources](#)


Development of Other Guidance

- [Essential Medicines List for Management of Patients admitted to Intensive Care Units with Suspected or Confirmed COVID-19 Diagnosis](#)
- [Technical specifications of medical devices for the case management of COVID-19 in healthcare settings](#)
- [Requirements and technical specifications of personal protective equipment \(PPE\) for the novel coronavirus \(2019-ncov\) in healthcare settings](#)

Regulatory Strengthening in the Americas

- PAHO has a strong relationship with regulatory authorities in the region
- Pan American Network for Drug Regulatory Harmonization
- National Regulatory Authorities of Regional Reference
- Assessment program
- Sub-regional regulatory mechanisms in Caribbean, Central America


Regulatory Situation in the Americas (N=35)




- ☐ A - States with National Regulatory Authority of Regional of Reference according to CD50.R9 (NRAr)
- ☐ B - States that have legal bases and organizational structures for a comprehensive regulatory system
- ☐ C - States that have some legal bases and organizational structures for a regulatory system
- ☐ D - States that do not currently have legal bases and/or organizational structures for a regulatory system

Association of Population and Absolute GDP with Limited Regulatory Capacity

A



B




Sub-Regional Mechanisms to be Aware of

- Within CARICOM block of countries, CARPHA/CRS
 - Reliance mechanism, with verification procedure- drugs, biologics, IVDs
 - Recommends products to MS
 - Post market surveillance system
- Within Central American countries, new regional mechanism
 - Joint reviews

Regulatory Support in a Pandemic

- Multiple regulatory functions implicated:
 - **Market authorization, post market surveillance, clinical trials, laboratory, inspections, licensing of establishments, lot release**
- We leverage tools/thinking from WHO Pandemic Influenza Preparedness Framework
- Have experience with other epidemic/pandemic situations



Major Regulatory Initiative in COVID-19

- Support National Regulatory Authorities in the Americas to better respond to COVID-19 pandemic:
 - Establish a network of high-level focal points from NRAs responsible for COVID-19 to enable information sharing and rapid response
 - Update legal and policy frameworks for regulatory response during COVID-19
 - Identify the regulatory challenges around COVID-19, and provide guidance to NRAs on regular basis



PROPOSED ACTIONS FOR MEMBER STATES

- Incorporate recommended regulatory approaches relative to the pandemic with regulatory functions.
- Promote the establishment of a regulatory crisis management committee that can articulate with other National Health Authorities and improve communication with other national government stakeholders, and civil society.
- Evaluate, identify and address regulatory gaps based on WHO/PAHO checklist
- Document regulatory actions taken during the crisis to improve transparency and monitor their impact.

Regulatory Support in a Pandemic

- Hold bi-weekly meetings on key regulatory topics
 - Hosted by PAHO Assistant Director Jarbas Barbosa

Regulatory considerations on authorization of the use of convalescent plasma (PC) to address the COVID-19 emergency, 22 April 2020


<https://iris.paho.org/handle/10665.2/52036>

Reliance for Emergency Use Authorization of Medicines and Other Health Technologies in a Pandemic (e.g. COVID-19)

<https://iris.paho.org/handle/10665.2/52027>


Crisis Management during an Epidemic: General guidelines for efficient response coordination by national regulatory authorities, May 2020

<https://iris.paho.org/handle/10665.2/52098>



REGULATORY ACTIONS DURING PANDEMIC:

Reliance for Emergency Use Authorization in a Pandemic



We are thinking about how we set up systems that will most efficiently get drugs, vaccines, diagnostics to populations in COVID-19- what do we need to do to prepare?

- Scope- drugs, vaccines, IVDs
- Conditions for declaring emergency
- Risk based approach- use reliance on reference authorities

Suggested Technical Requirements for Pharmaceuticals, Vaccines, and IVDs for EUA

- Assurance of sameness
 - Cover letter, marketing authorization certificate
- Product description
 - Summary of product characteristics or equivalent, package insert
- Manufacturing information
 - List of all sites involved in manufacture (API and FPP)
 - FPP GMP certificate or ISO 13485 certificate if IVD
- Product labeling
 - PDF artworks in national language



Regulatory Support in a Pandemic

- Upcoming topics
 - Clinical trials regulation
 - Post market surveillance
 - Donations
 - TBD- welcome your thoughts

Clinical Trials Regulation Guidance (Upcoming)


- Basic elements of clinical trials regulation
- How to move expeditiously during pandemic situations
- How to leverage efficiencies such as collaborative reviews, reliance on decisions

REGULATORY ACTIONS DURING PANDEMIC:

Topic-Specific Meetings

- Evidence in the Treatment of COVID-19
- Regulation of ventilators in COVID-19
- Training sessions on Quantification Tool of medicines, medical supplies and PPEs
- Regulation and procurement of PPE in the COVID-19 context
- Ethics review and oversight of COVID-19-related research

REGULATORY ACTIONS DURING PANDEMIC



HOME ABOUT US **COVID-19 + MT** GET IN TOUCH ENGLISH ESPAÑOL PORTUGUÊS

Regional Platform on Access and Innovation for Health Technologies PRAIS

Pan American Health Organization

World Health Organization REGIONAL OFFICE FOR THE AMERICAS

Home > COVID-19 + MT

COVID-19 + MT

Suggested COVID-19 information resources links related to Medicines, In-Vitro Diagnostics (IVDs) and other Medical Devices

Last Updated 11 May 2020 by Fernanda Lessa

General resources

- **PAHO**

[PAHO COVID-19 web page](#)

[Technical Documents](#) Including:

- * [Regulatory considerations on authorization of the use of convalescent plasma \(PC\) to address the COVID-19 emergency.](#)
- * [Reliance for Emergency Use Authorization of Medicines and Other Health Technologies in a Pandemic \(e.g. COVID-19\).](#)
- * [Technical specifications on medical devices](#)

Back	Alt+Left Arrow
Forward	Alt+Right Arrow
Reload	Ctrl+R
Save as...	Ctrl+S
Print...	Ctrl+P
Cast...	
Translate to English	
View page source	Ctrl+U
Inspect	Ctrl+Shift+I

PRAIS NEWS

COVID-19: Keep posted!

Delegados Centroamericanos


Health Technology Planning & Management

VIDEOS

Media briefing on COVID-19

<https://prais.paho.org/en/home/>

REGULATORY ACTIONS DURING PANDEMIC



- Publication of updated regulatory actions on COVID-19 of the NRA of regional reference:
 - ANMAT, Argentina
 - ANVISA, Brazil
 - Health Canada
 - ISP, Chile
 - INVIMA, Colombia
 - CECMED, Cuba
 - COFEPRIS, Mexico
 - US FDA, USA

FIFARMA and PAHO

- How can we work more closely in this pandemic?

Thank You

Thoughts?

- prestoncha@paho.org

Questions?